Vectus Biosystems Ltd Secures US Agent for VB0004 FDA Pathway
US regulatory agent secured to drive VB0004 FDA pathway
Vectus Biosystems (ASX:VBS) has formally engaged Cardinal Health Regulatory Services (CHRS) as its United States (US) Regulatory Agent, appointing the consultancy as the primary point of contact for all FDA-facing regulatory activities.
The engagement covers Vectus’ lead compound, VB0004, and potentially its other pipeline assets as they advance. Announced on 13 July 2026, the move establishes the US regulatory pathway for a first-in-class oral therapy targeting idiopathic pulmonary fibrosis (IPF).
For a clinical-stage biotech, securing an experienced regulatory agent marks the transition from research toward a structured US development programme.
When big ASX news breaks, our subscribers know first
What the CHRS engagement covers
Under the engagement, CHRS will facilitate and prepare all FDA-facing communications, interactions and submissions on behalf of the Company.
The specific submissions CHRS will handle include:
- Orphan Drug Designation Request
- pre-Investigational New Drug (pre-IND) communications
- the IND application for VB0004 in IPF
CHRS is described as a leading US regulatory affairs consultancy with deep expertise in FDA submissions and drug development strategies. Appointing an experienced agent is intended to de-risk the regulatory process and signals a clear structure behind the Company’s US ambitions.
Dr Tara Speranza was appointed as combined CEO and CTO in May 2026, with her remuneration structured around share price vesting hurdles between 20 and 30 cents, directly aligning executive incentives with the milestones required to advance VB0004 through the US regulatory process.
Dr Tara Speranza, CEO and CTO
“Appointing CHRS as our US Regulatory Agent is an important milestone in establishing a clear regulatory pathway for VB0004 with the FDA. Its extensive experience in regulatory strategies and submissions will be invaluable as we advance preparations for our US development programme. This represents another important step toward bringing our first-in-class oral therapy to patients living with IPF, where there remains a significant unmet medical need.”
Understanding VB0004 and the IPF opportunity
What is VB0004?
VB0004 is a first-in-class oral Natriuretic Peptide Receptor C agonist in development for the treatment of IPF. In plain terms, it is an experimental medicine designed to target the biological process that drives scarring in lung tissue.
The compound has demonstrated the ability to reverse established fibrosis in pre-clinical models. It has also successfully completed a Phase Ia clinical study in healthy volunteers, establishing a favourable safety and pharmacokinetic profile.
Phase Ia refers to the earliest stage of human testing, where a treatment is assessed for safety and how the body processes it, rather than for effectiveness against disease.
Why IPF matters
IPF is a progressive, and often fatal, lung disease with significant unmet medical need. Current treatment options remain limited, which is why new approaches attract clinical and commercial interest.
An oral first-in-class candidate addressing a serious unmet need could represent a differentiated market opportunity, though it remains at an early clinical stage.
Where this fits in the Vectus pipeline
Vectus is an Australian clinical-stage biotechnology company developing novel antifibrotic therapies, with an initial focus on advancing VB0004 for IPF.
Beyond IPF, the Company is advancing a broader pipeline targeting cardiovascular, renal and liver fibrosis, leveraging a platform approach to address diseases driven by pathological tissue scarring.
The commercial potential of that platform has been externally validated through a licensing agreement with an international biotechnology company for one of Vectus’ renal fibrosis assets, showing a pathway for potential future milestone and royalty revenues.
The renal fibrosis licensing agreement, which saw Vectus exchange its VB4-P5 compound for a 9.9% equity stake in Nasdaq-listed XORTX Therapeutics, was structured to avoid shareholder dilution while freeing internal resources to concentrate on VB0004.
| Development milestone | Investor significance |
|---|---|
| Phase Ia completed (safety & PK) | Early clinical validation achieved |
| CHRS engaged as US Regulatory Agent | US FDA pathway now established |
| Orphan Drug + pre-IND + IND planned | Clear near-term regulatory roadmap |
| Existing renal asset licensing deal | Potential milestone/royalty revenue |
The next major ASX story will hit our subscribers first
What comes next for Vectus
US regulatory activities are now underway to establish the foundation for future clinical development in the US.
The planned FDA submissions, spanning the Orphan Drug Designation Request, pre-IND communications and the IND application, form the path toward US clinical development for VB0004.
Building on completed Phase Ia data and existing external validation through its renal fibrosis licensing agreement, the engagement moves the lead compound closer to the clinic in the US. No specific submission dates or timelines were disclosed in the announcement.
Don’t Miss the Next Biotech Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers are already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to make sure the next major ASX announcement lands in your inbox before the market moves.